Skip to main content
Log in

Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna

A case report of a patient with seronegative rheumatoid arthritis and rheumatoid vasculitis

Toxische epidermale Nekrolyse unter Therapie mit Cyclophosphamid und Mesna

Eine Kasuistik eines Patienten mit seronegativer rheumatoider Arthritis und rheumatoider Vaskulitis

  • Kasuistiken
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Abstract

Rheumatoid vasculitis usually occurs on the background of seropositive rheumatoid arthritis, although in rare cases the patients can be seronegative. We report a woman with seronegative rheumatoid arthritis with rheumatoid vasculitis who developed toxic epidermal necrolysis involving most of her body surface area, while on therapy with intravenous cyclophosphamide and mesna. After withdrawal of suspected offending agents, administration of intravenous immunoglobulin, and supportive therapy, she had a favorable outcome. Such an occurrence is rare and serves to educate about a potentially life-threatening adverse event associated with a commonly used immunosuppressive agent.

Zusammenfassung

Eine rheumatoide Vaskulitis tritt meist vor dem Hintergrund einer seropositiven rheumatoiden Arthritis auf, selten auch bei Seronegativität. Berichtet wird über eine Patientin mit seronegativer rheumatoider Arthritis, die unter Therapie mit i.v. Cyclophosphamid und Mesna eine toxische epidermale Nekrolyse im Bereich von nahezu der gesamten Körperoberfläche entwickelte. Nach Sistieren der im Verdacht stehenden Substanzen, i.v. Gabe von Immunglobulinen und Implementierung einer supportiven Therapie kam es zu einem günstigen Verlauf und Outcome. Die Schilderung dieses selten vorkommenden Ereignisses soll für eine potenziell lebensbedrohliche Nebenwirkung in Verbindung mit einem häufig eingesetzten Immunsuppressivum sensibilisieren.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Turesson C, Matteson EL (2009) Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 21:35–40

    Article  PubMed  Google Scholar 

  2. Bartels CM, Bridges AJ (2010) RV: vanishing menace or target for new treatments? Curr Rheumatol Rep 12:414–419

    Article  PubMed  PubMed Central  Google Scholar 

  3. Worswick S, Cotliar J (2011) Stevens-Johnson syndrome and TEN: a review of treatment options. Dermatol Ther 24:207–218

    Article  PubMed  Google Scholar 

  4. Scott DG, Bacon PA (1984) Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic RV. Am J Med 76:377–384

    Article  CAS  PubMed  Google Scholar 

  5. Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310–317

    Article  CAS  PubMed  Google Scholar 

  6. Bastuji-Garin S, Fouchard N, Bertocchi M et al (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149–153

    Article  CAS  PubMed  Google Scholar 

  7. Ikeda E, Uchigasaki S, Endo M et al (1998) RV in a patient with seronegative rheumatoid arthritis. Eur J Dermatol 8:268–270

    CAS  PubMed  Google Scholar 

  8. Assier-Bonnet H, Aaractingi S, Cardranel J et al (1996) Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol 135:864–866

    Article  CAS  PubMed  Google Scholar 

  9. Patel MP, Kute VB, Vanikar AV, Trivedi HL (2014) Cyclophosphamide-induced toxic epidermal necrolysis: vigilance needed. Clin Kidney J 7:323–324

    Article  PubMed  PubMed Central  Google Scholar 

  10. Leititis JU, Burghard R, Rietschel E et al (1985) Stevens-Johnson syndrome during an immunosuppressive therapy with cyclophosphamide and prednisone. Klin Padiatr 197:441–442

    Article  CAS  PubMed  Google Scholar 

  11. Fernandes NC, Menezes M (2013) Pulse therapy in pemphigus: report of 11 cases. An Bras Dermatol 88:672–675

    Article  PubMed  PubMed Central  Google Scholar 

  12. Friedman OM, Seligman AM (1954) Preparation of N-phosphorylated derivatives of bis-β-chloroethylamine1a. J Am Chem Soc 76:655–658

    Article  CAS  Google Scholar 

  13. Papay J, Yuen N, Powell G et al (2012) Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf 21:289–296

    Article  PubMed  Google Scholar 

  14. Chung WH, Hung SI, Chen YT (2007) Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 7:317–323

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with ethical guidelines

Conflict of interest. A.C. Chowdhury, D.P Misra, P.S. Patro, and V. Agarwal state that there are no conflicts of interest.

Written informed consent was sought from the patient prior to submitting the article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D.P. Misra.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chowdhury, A., Misra, D., Patro, P. et al. Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna. Z Rheumatol 75, 200–202 (2016). https://doi.org/10.1007/s00393-015-1632-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-015-1632-z

Keywords

Schlüsselwörter

Navigation